Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics Inc

Vaxart

CureVac B.V

Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.

Got $3,000? These 4 Emerging Coronavirus Vaccine Stocks Look Like a Bargain

Inovio Pharmaceuticals

Short-sellers are betting against these stocks big time. But that could set up big opportunities for investors if these biotechs have positive news on the way.

3 Heavily Shorted Coronavirus Vaccine Stocks

EMERYVILLE, Calif., Aug.  31, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that  Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on Monday, September 14, at 10:00 a.m. ET.

Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

Dynavax: Ready To Return To Bullish

EMERYVILLE, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the  Bill & Melinda Gates Foundation  of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant to support the global COVID-19 response. These efforts will support capacity of up to 750 million adjuvant doses annually, which can be further increased if needed.

Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response

This biotech has a vaccine for treating hepatitis B and is now tackling COVID-19. But it's still valued at less than $1 billion.

Finally, Some Good News for Dynavax Technologies

Heat Biologics

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today

iShares Nasdaq Biotechnology ETF

ImmunoGen

Lexicon Pharmaceuticals

Viking Therapeutics

Xencor

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

5 Speculative Biotechs With 50% to 300% Implied Upside

Amgen

Gilead Sciences

Pfizer

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -12.50% and -53.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Reports Q2 Loss, Misses Revenue Estimates

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2020 Results - Earnings Call Transcript

EMERYVILLE, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the second quarter of 2020.

Dynavax Announces Second Quarter 2020 Financial Results

Moderna

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

EMERYVILLE, Calif., July  30, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close.

Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Dynavax Technologies (DVAX) Report Negative Q2 Earnings? What You Should Know

BioNTech SE

GlaxoSmithKline

Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.

Coronavirus Vaccine Development Puts These Stocks in Focus

Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.

Is a Beat in Store for Dynavax (DVAX) This Earnings Season?

Dynavax Technologies (DVAX) closed the most recent trading day at $10.12, moving -0.3% from the previous trading session.

Dynavax Technologies (DVAX) Stock Moves -0.3%: What You Should Know

EMERYVILLE, Calif., July  21, 2020  (GLOBE NEWSWIRE) --   Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of  Ms. Julie Eastland  and  Mr. Brent MacGregor  to its Board of Directors.

Dynavax Announces the Appointment of Two New Board Members

Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.

Dynavax Signs a Pact to Develop Universal Influenza Vaccine

Dynavax (NASDAQ: DVAX) shares are trading higher on Friday amid strength in vaccine stocks for the session.

Why Dynavax's Stock Is Trading Higher Today

Shares of Dynavax Technologies Corp. DVAX, -2.66% gained 0.2% in trading on Thursday after the company announced that it will work with the Icahn School of Medicine at the Mount Sinai hospital system in New York on a universal influenza vaccine.

Dynavax, Mount Sinai to work on universal flu vaccine

Altimmune

NantKwest

Novavax

VBI Vaccines

My COVID-19 Vaccine Report Card

NEW YORK and EMERYVILLE, Calif., July  16, 2020  (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) today announced they have entered into a collaboration to develop a universal influenza (flu) vaccine. Mount Sinai’s current work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program established by NIAID.  The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin (cHA) designed to protect against all strains of influenza in combination with Dynavax’s CpG 1018TM adjuvant.

Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.

News for Dynavax Technologies Stock (DVAX)